{"name":"Shanghai EpimAb Biotherapeutics Co., Ltd.","slug":"shanghai-epimab-biotherapeutics-co-ltd","ticker":"","exchange":"","domain":"shanghaiepimabbiotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"EMB-01","genericName":"EMB-01","slug":"emb-01","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"EMB-01","genericName":"EMB-01","slug":"emb-01","phase":"phase_2","mechanism":"EMB-01 is an investigational monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQLUN4Ml9VWUwtdl9lTEdyQXpZNHJjcUtSeW0tRnhHMEJRdEk5djc0WWxRV2FQWU9hMDIyMEVXMlVIRnZqNTBrbktyVnNhQ0FLYi02TFBWUUJyaUxjenFCY2RON0ZoLTV1RDdlbEd6MzNfdW4tZTZWd0pvS1AxT0prX0dSd1NJd3RLdDd2b3kteWJlZnpOcExGSWY2emM5Wk1xa0NTODVITzk?oc=5","date":"2026-02-10","type":"pipeline","source":"BioWorld News","summary":"Almirall files CTA for bispecific antibody for atopic dermatitis - BioWorld News","headline":"Almirall files CTA for bispecific antibody for atopic dermatitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxOMXR4cGEwaExmNUd4SUUwcWVQRFVxX0FGYkIwb0xhSGRCeWQ3aDBra0U2bmUyMFVHX1d1UFhaeHlIWDdBdGdxbTFzSkUxckFqVUJDRXFKdUVBNi1TY3ltVVpEUndCYXZGYWt6QVhSeXpiSXBZZW53M25HNHRBZXpIY3VWUkc0THlBZzRDVzE0TFVjaUlBTFpzWms0T0NuTnNLMEYyRDU5anF4SWQ5MVJXX3hXbG84ZHFLSVRDWDJwMWRiOUlOcWlsWHJZX2hsNktsSmFlSmpRYmQ4dllObEtuQ0JmLVdRVm9GYzdTMFJvckFpUW81emRFcUxSSVZNNTctdXF2alRxZUh4WkhjbmRrY19GOHFjd1k2?oc=5","date":"2026-02-09","type":"deal","source":"globenewswire.com","summary":"EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall - globenewswire.com","headline":"EpimAb Biotherapeutics Announces the First CTA Filing of a FIT-IG® Bispecific Antibody by its License Partner Almirall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPQ0IyRmpWZzhoSnhlMVFEdVdtRzM2TjRtN0FfSXp5YjBSMHJVcGZwNlJxR09OODhWQWhIM3NRcV9pdEczQUhiaEs1aXpXYVlRWFlWb1k5QVVfd0t5bmQxRmVGblpDZVM4SmRtN2taaExmRU9KN3BmLU95bVRRM1V4aWtYaEZQVGpZNzRsOEVrSTdVc2FiVTFDcDJhb19DczA5M2IzM0FR?oc=5","date":"2025-12-09","type":"pipeline","source":"BioWorld News","summary":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025 - BioWorld News","headline":"73 Chinese biotech, med-tech companies file for HK IPOs in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSXpxeWZydHlDUTZXekpJQ29teFdNQjFhV1ZSakZFWm1UNU1wN3lYN0ExVTlXOXcybDNRN1IwU0FGVkwzT0tZNXJmNnl3UlhseUE4NTVLbUl0TVlFT0JYOEJLdzhtTVNSNkF0N1YyMnFMb0xXRFVMbjhoMVhsTUdDV1JUMGlac2lERGlKWFIydjM4Z1U0NTFmalU0SWtkcDAzOUdZRElnQQ?oc=5","date":"2025-06-12","type":"deal","source":"BioWorld News","summary":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld News","headline":"Cullinan deals $712M to test Genrix bispecific TCE in autoimmune","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPQS15S1RSdDJTd0hUNWpSNDlOcnU5UTV3WlJlSVlZTnIzOTRjMjVCRWsyWGZGdmdpTmFEM282MTg2Q0M5VTZCTWFXbE8wZktac0ZUYWIybFlOQUNPOXNqTGduc0Q1ZHE5ZVNlRkFPZ1hqZmZHMGFzdkl4Z1hMc0VHeXcyZWUxVTR2VnJTa2JuTFVzaktUX1JRY1V4aWlBRzliaHc?oc=5","date":"2025-06-03","type":"deal","source":"BioWorld News","summary":"Epimab sells bispecific T-cell engager to Juri in $210M deal - BioWorld News","headline":"Epimab sells bispecific T-cell engager to Juri in $210M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNMGVvUF9uLVVSRE52V1JvZG95N3l5Sk5fU21qdlpVQmJvcVpiQkhsU0E3bmdneXkyS0RfTGNPUzRQRHdRd09GZURPazN2Q3AtbE1fNmN4RXZ5YnJhcEpBUi1ueFJNelBtdUdNYkRpRk5FbFozSDN3ZmQ4RldtNmpJY2dQYUtab3dGczNON0w3andCZFNDdTdBbHZadnVrS3gtemFVVw?oc=5","date":"2025-05-27","type":"deal","source":"Fierce Biotech","summary":"Biotech incubated by TCG Labs inks $210M deal for EpimAb's T-cell engager - Fierce Biotech","headline":"Biotech incubated by TCG Labs inks $210M deal for EpimAb's T-cell engager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOYThaYWxZTVRpZzl4NmZwWGV0QzAzaDVmOEhzeEtfSXVycy1fdEw5aDVuWXJQdi1sd3ZHWTNvamthcVdFN1lySUF3M0RPdFNoWUxDSWNnSDNwMUVQaDRSMllhZDNfNkZGdTNmeXNVc3FLcm5kTVBUd2pHVGlmZkpzaEFDZ0o1SV9UUWFHam9jVV9YMDZQWWhZWVhuTWN3ZEtuaVJuY3Nn?oc=5","date":"2024-12-17","type":"deal","source":"BioWorld News","summary":"Candid, Epimab ink $1B T-cell engager deal in autoimmune disease - BioWorld News","headline":"Candid, Epimab ink $1B T-cell engager deal in autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingJBVV95cUxQbWxpWFNBSEtrMk1UcFNuYmtSbEF0TUwyU2lzZFhsT1Q3UG9SUHFPS250QTVLSUUwS0M2WGZJVWpRUmtrcWlQMEJQMmxGQVNtUnlHeXBOUmY0QVg5Rmx0bjVqTjNZRVlsbDV1bi1ncS04OUN5cnlpX3pZOGdhZDlGQVE1S29mT0psd2VrTGpsWGNnOTR2c01xSmdPUlVUUUJ4ZVpOMFNlV2FtZ1lNZUUtbkU3VXNXdWZJV1BiLThnMnlUTEdENmowYjFDSlpESmdoR1Uzc2RrZERyeDk4ODhac2oza3FYekJwT3lUN0RsazlnTDBPeXNEN09ueVQxVnl5bmpKSnhYSGZGMURNYXR2RFhUYnpfTmpET0tRRXZB?oc=5","date":"2024-09-03","type":"pipeline","source":"globenewswire.com","summary":"EpimAb Biotherapeutics and Vignette Bio Announce Strategic - globenewswire.com","headline":"EpimAb Biotherapeutics and Vignette Bio Announce Strategic","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}